Jonathan W. Riess, MD, MS, on Novel Therapies on the Horizon for EGFR-Mutated Non–Small Cell Lung Cancer

Posted: Wednesday, June 7, 2023

Jonathan W. Riess, MD, MS, of the University of California, Davis Comprehensive Cancer Center, discusses several new research directions for treating patients with non–small cell lung cancer with an EGFR mutation. He explores the use of new targeted agents such as small molecules and antibody-drug conjugates in first-line and later-line treatment scenarios for this type of lung cancer.